ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1025

Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients

Sharon Dowell1, Mercedes Quinones2, Tahereh Jamshidi3, Ilona Jileaeva4, Oshoze Kadiri4 and Gail Kerr5, 1NEA Baptist Memorial Hospital, Jonesboro, AR, 2Washington DC VA Medical Center, Bethesda, MD, 3Howard University Hospital, Bethesda, MD, 4Howard University, Washington, DC, 5Washington DC VAMC/Georgetown and Howard Universities, Washington, DC

Meeting: ACR Convergence 2023

Keywords: Biologicals, Disease Activity, Disparities, education, patient, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A successful treat to target (T2T) strategy in ethnic minority (EM) patients with rheumatoid arthritis (RA) could improve patient outcomes and help reduce healthcare disparity but requires patient engagement. In one prospective EM RA database, a low rate of meaningful clinical response was due in part to decreased biologic DMARD (bDMARD) utilization. Other known contributors include distrust of the medical system and medication hesitancy embedded in cultural norms. Education is a critical factor in encouraging self-active participation, medication adherence, and commitment to healthcare goals, but often requires lengthy one-on-one sessions with a provider. The aim of this study was to observe the effect of a Rheumatology Care Coordinator (RCC)-led education program on patient outcomes before and after a targeted education program focused on the T2T paradigm in RA.

Methods: Participants with RA and moderate-to-high disease activity (CDAI >10, RAPID3 >6) were enrolled. Each participant completed 5 T2T-focused education sessions scheduled with routine rheumatology office visits and facilitated by a RCC who completed 6 weeks of training on RA patient education. Translation services were utilized for non-English speaking participants. Demographic and clinical characteristics were recorded, as well as race and ethnicity of providers. Disease activity measures (CDAI and RAPID3), the Arthritis Community Research Evaluation Unit (ACREU) Patient Knowledge Questionnaire (PKQ), Compliance questionnaire and Trust in Physician Scale scores were recorded at Visit 1 and Visit 5. Meaningful clinical reduction in RAPID3 (-3.8) and CDAI (- 6) at Visit 5 was calculated. Descriptive statistics were used for demographic and clinical characteristics. Student’s t-test was used to assess RA-related knowledge acquisition, change in compliance, and change in disease activity.

Results: Over a mean study enrollment period of 10 (±3.4) months, there were 29 participants of mean age 57.52 ± 13.81 years, predominantly of African descent and female sex (83%) (Table 1). Most had at least high school education, one with a post graduate degree. The 4 participating providers were non-White. There was a high level of physician trust, which remained stable at the end of the study. There was no significant difference in ACREU scores (t = -0.07, p-value = 0.94), and although compliance scores improved, the difference was not significant (t = -1.94, p-value = 0.06). A significant decrease in RAPID3 (t = 2.70, p-value < 0.05, mean difference -3.98) and CDAI (t = 4.36, p-value < 0.05, mean difference -8.60) was seen, with meaningful clinical reduction in disease activity in 48% and 58% of patients, respectively. Almost 50% of participants had a change in DMARD, with 5 patients starting a new biologic therapy.

Conclusion: In a small urban cohort of predominantly African American patients with high school education, a successful T2T regimen was independent of educational level and targeted patient education. Achieving meaningful reduction in disease activity can be achieved in a setting where high physician trust enables shared decisions. The role of patient-provider race and ethnicity in achieving disease remission needs further evaluation.

Supporting image 1

*Disease modifying antirheumatic drug (DMARD), conventional synthetic DMARD (csDMARD), Biologic DMARD (bDMARD)
**The Arthritis Community Research Evaluation Unit Patient Knowledge Questionnaire (ACREU_PKQ)
is scored out of 31. Compliance questionnaire is scored out of 20, and the Trust in Physician Scale is scored out of 55.


Disclosures: S. Dowell: Aurinia, 6, Bristol-Myers Squibb(BMS), 5, Janssen, 1; M. Quinones: Bristol-Myers Squibb(BMS), 5, CVS Health - CVS Caremark, 2, Pfizer, 5; T. Jamshidi: None; I. Jileaeva: None; O. Kadiri: None; G. Kerr: AstraZeneca, 2, Aurinia, 6, Horizon, 2, Janssen, 2, Pfizer, 1, Sanofi, 2.

To cite this abstract in AMA style:

Dowell S, Quinones M, Jamshidi T, Jileaeva I, Kadiri O, Kerr G. Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/embedding-treat-to-target-principles-in-rheumatoid-arthritis-patient-education-in-routine-care-of-ethnic-minority-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/embedding-treat-to-target-principles-in-rheumatoid-arthritis-patient-education-in-routine-care-of-ethnic-minority-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology